Gilead Sciences, Inc. (GILD) — 67.01 (-0.64)
Key Metrics & Ratings
- symbol GILD
- Rev/Share 21.9471
- Book/Share 17.8221
- PB 4.4596
- Debt/Equity 1.1647
- CurrentRatio 1.3406
- ROIC 0.1356
- MktCap 99035259200.0
- FreeCF/Share 6.3894
- PFCF 12.4198
- PE 16.8836
- Debt/Assets 0.4153
- DivYield 0.0377
- ROE 0.2749
- Rating A+
- Score 5.0
- Recommendation Strong Buy
- P/E Score 5.0
- DCF Score 5.0
- P/B Score 5.0
- D/E Score 4.0
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | GILD | Maxim Group | -- | Buy | $90 | $85 | May 1, 2024 |
| Upgrade | GILD | HSBC Securities | Reduce | Hold | -- | $69 | April 24, 2024 |
| Downgrade | GILD | Truist | Buy | Hold | $91 | $82 | Feb. 22, 2024 |
| Initiation | GILD | Deutsche Bank | -- | Hold | -- | $75 | Nov. 9, 2023 |
News
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Published: May 10, 2024 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
Published: May 06, 2024 by: InvestorPlace
Sentiment: Positive
If you really want to maximize your return potential, then acquiring stocks near 52-week lows could present a viable opportunity. Stated simply, it's a way to practice buying low and selling high.
Read More
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Published: April 15, 2024 by: The Motley Fool
Sentiment: Negative
Walgreens is still reeling from years of mismanagement. Gilead Sciences looks reliable, but is growing slowly.
Read More
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
Published: April 09, 2024 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.
Read More
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
Published: April 09, 2024 by: InvestorPlace
Sentiment: Positive
With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential.
Read More
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
Published: April 05, 2024 by: The Motley Fool
Sentiment: Positive
Starbucks, BCE, and Gilead Sciences pay dividends that yield well above the S&P 500 average. These companies all have strong businesses that can make for ideal long-term investments.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: April 03, 2024 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
My April Dividend Stock Buys With Yields Up To 12%
Published: April 02, 2024 by: Seeking Alpha
Sentiment: Positive
My April Dividend Stock Buys With Yields Up To 12%
Read More
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Published: March 28, 2024 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease. Vemlidy is a targeted prodrug of tenofovir that was approved by the F.
Read More
7 Value Stocks to Buy at a 52-Week Low in March
Published: March 28, 2024 by: InvestorPlace
Sentiment: Positive
When it comes to finding the best value stocks to buy, sometimes you have to go against the grain. That is, dive into stocks that have fallen out of favor with the market, to assess whether investor sentiment is on the money, or an overreaction.
Read More
Gilead Sciences Announces Completion of Acquisition of CymaBay
Published: March 22, 2024 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to.
Read More
Gilead Sciences Finally Starts Succeeding
Published: March 21, 2024 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones planned for 2024.
Read More
Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know
Published: March 19, 2024 by: Zacks Investment Research
Sentiment: Neutral
Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.
Read More
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
Published: March 18, 2024 by: Business Wire
Sentiment: Neutral
LAFAYETTE, Colo.--(BUSINESS WIRE)--The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead's Relink grant program. In this first round, CDA Foundation distributed a total of 2.1 million dollars to the following 14 grantees: O.
Read More
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Published: March 15, 2024 by: Reuters
Sentiment: Positive
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that business told Reuters.
Read More
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
Published: March 13, 2024 by: Zacks Investment Research
Sentiment: Negative
Gilead Sciences (GILD) closed the most recent trading day at $75.94, moving +1.15% from the previous trading session.
Read More
Protesters Keep Heat on Greedy Gilead over Price Gouging
Published: March 12, 2024 by: Business Wire
Sentiment: Neutral
MIAMI--(BUSINESS WIRE)--Protesters Keep Heat on Greedy Gilead over Price Gouging.
Read More
AHF Keeps Pressure on ‘Greedy Gilead' Over Price Gouging
Published: March 11, 2024 by: Business Wire
Sentiment: Neutral
MIAMI--(BUSINESS WIRE)--AHF Keeps Pressure on ‘Greedy Gilead' Over Price Gouging.
Read More
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
Published: February 13, 2024 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Read More
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Published: February 12, 2024 by: Investopedia
Sentiment: Positive
Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.
Read More
Gilead to buy CymaBay Therapeutics for $4.3 billion
Published: February 12, 2024 by: Invezz
Sentiment: Positive
CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.50 per share.
Read More
Drugmaker Gilead to acquire CymaBay for $4.3 bln
Published: February 12, 2024 by: Reuters
Sentiment: Positive
Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.
Read More
Gilead strikes deal to acquire CymaBay for $4.3 billion
Published: February 12, 2024 by: Market Watch
Sentiment: Positive
Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for a total deal equity value of $4.3 billion. CymaBay's lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
Read More
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: February 12, 2024 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns wit.
Read More
Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC
Published: February 09, 2024 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead's longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100.
Read More
7 Biotech Stocks Fighting America's Deadliest Diseases
Published: February 08, 2024 by: InvestorPlace
Sentiment: Positive
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
Read More
Why Gilead Sciences Stock Dropped Today
Published: February 07, 2024 by: The Motley Fool
Sentiment: Negative
Gilead delivered a mixed fourth quarter relative to expectations. The biopharma giant also issued underwhelming forward guidance.
Read More
Daily Dividend Report: Mastercard, MMM, Gilead, Keurig, Zoetis
Published: February 07, 2024 by: Forbes
Sentiment: Positive
Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A common stock and Class B common stock as of April 9, 2024.
Read More
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
Published: February 07, 2024 by: Zacks Investment Research
Sentiment: Neutral
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
Read More
Brian Belski makes big trades on Snap, Chesapeake Energy, DoorDash, Gilead, and UnitedHealth
Published: February 07, 2024 by: CNBC Television
Sentiment: Neutral
Brian Belski, chief investment strategist at BMO Capital Markets, joins 'Halftime Report' to break down his latest trades.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Mr. Daniel P. O'Day
- Employees 18000